Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-09-21 09:53 |
Orexo presents an update on the US opioid dependence market, and the commercial…
|
English | 169.3 KB | ||
| 2012-09-21 09:53 |
Orexo ger en uppdatering om den amerikanska marknaden för opiatberoende och möj…
|
Swedish | 97.6 KB | ||
| 2012-09-17 11:29 |
Orexo invites to a Zubsolv™ (OX219) information meeting on September 21 in Stoc…
|
English | 33.0 KB | ||
| 2012-09-17 11:29 |
Orexo bjuder in till Informationsträff kring Zubsolv™ (OX219) den 21 september …
|
Swedish | 32.3 KB | ||
| 2012-09-06 12:59 |
Swedish specialty pharmaceutical company Orexo announced today the submission o…
|
English | 98.2 KB | ||
| 2012-09-06 12:59 |
Orexo bekräftar idag inlämningen av en registreringsansökan till den amerikansk…
|
Swedish | 97.0 KB | ||
| 2012-08-21 07:59 |
Orexo reports successful achievement of product stability data for OX219 – subm…
|
English | 32.8 KB | ||
| 2012-08-21 07:59 |
Orexo erhåller stabilitetsdata för OX219 – Registreringsansökan i USA tidigarel…
|
Swedish | 94.9 KB | ||
| 2012-07-23 07:59 |
Orexo reports positive feedback from pre-NDA meeting with FDA – clearing path f…
|
English | 189.1 KB | ||
| 2012-07-23 07:59 |
Orexo rapporterar om positiv feedback från pre-NDA möte med FDA – banar väg för…
|
Swedish | 199.9 KB | ||
| 2012-07-16 07:59 |
Buyback of company shares
|
English | 26.5 KB | ||
| 2012-07-16 07:59 |
Återköp av egna aktier
|
Swedish | 29.0 KB | ||
| 2012-07-13 17:59 |
Report from the extraordinary general meeting in Orexo AB, 13 July 2012
|
English | 41.8 KB | ||
| 2012-07-13 17:59 |
Kommuniké från extra bolagsstämma i Orexo AB den 13 juli 2012
|
Swedish | 24.7 KB | ||
| 2012-07-12 07:59 | Swedish | 1.1 MB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
